Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03573882 · ClinicalTrials.gov registry record · Phase 3

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

A Phase 3 study, sponsored by Pfizer.

Terminated
Registry status
Phase 3
Development phase
179
Enrollment target

NCT03573882 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 179 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03573882, a Phase 3 study, was terminated before completion, sponsored by Pfizer.

TERMINATED
Registry status
Phase 3
Development phase
179 participants
Enrollment target

Study Summary

Open Label Extension Study of Voxelotor Clinical Trial Participants with Sickle Cell Disease Who Participated in Voxelotor Clinical Trials

Interventions

  • DRUG Voxelotor

Trial Details

FieldValue
Enrollment Target 179 participants
Start Date 2018-06-06
Est. Completion 2024-11-12
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT03573882

The ClinicalTrials.gov registry entry for NCT03573882 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Voxelotor is the first listed.

NCT03573882 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03573882 about?

NCT03573882 is a clinical study titled "Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031". Open Label Extension Study of Voxelotor Clinical Trial Participants with Sickle Cell Disease Who Participated in Voxelotor Clinical Trials

What is the current status of trial NCT03573882?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 179 participants. The study started on 2018-06-06. Estimated completion is 2024-11-12.

What interventions are being tested in trial NCT03573882?

The interventions under investigation include: Voxelotor (DRUG).

Who is sponsoring clinical trial NCT03573882?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.